Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 06 2022 - 6:00PM
Business Wire
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage
biopharmaceutical company dedicated to delivering targeted
therapies for rare cancers, granted stock options to seven new
employees as approved by the Compensation Committee of the
Company’s Board of Directors, under Sierra Oncology’s 2018 Equity
Inducement Plan. The 2018 Equity Inducement Plan is used
exclusively for the grant of equity awards to individuals as an
inducement material to such individuals entering into employment
with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.
The employees received options to purchase a total 55,500 shares
of Sierra’s common stock. The options have an exercise price of
$33.76 per share, which is equal to the closing price of Sierra’s
common stock on the date of grant. The options will vest and become
exercisable as to 25% of the shares on the first anniversary of
each recipient’s start date, and then will vest and become
exercisable as to the remaining 75% of shares in 36 equal monthly
installments following the first anniversary, subject to each
employee’s continued employment with Sierra on such vesting dates.
The options are subject to the terms and conditions of Sierra’s
2018 Equity Inducement Plan, and the terms and conditions of the
stock option agreement covering each grant.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a
mission to deliver targeted therapies that treat rare forms of
cancer. We harness our deep scientific expertise to identify
compounds that target the root cause of disease. Our team takes an
evidence-based approach to understand the limitations of current
treatments and explore new ways to change the cancer treatment
paradigm. Together we are transforming promise into patient
impact.
For more information, visit www.SierraOncology.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406006060/en/
Investor Contact
DeDe Sheel 415.732.9828 dsheel@sierraoncology.com
Media Contact
Lauren Musto 615.351.7777 lmusto@sierraoncology.com
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sierra Oncology (NASDAQ:SRRA)
Historical Stock Chart
From Apr 2023 to Apr 2024